Inspira™ Technologies Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest
Inspira Technologies (Nasdaq: IINN) has introduced the INSPIRA Cardi-ART, a portable modular device designed to provide oxygen to the brain during cardiac arrest. This innovation targets the $39.8 billion global cardiac arrest market, expanding Inspira's potential market to approximately $58.8 billion. The device aims to improve survival rates for cardiac arrest patients, particularly outside hospitals where the mortality rate is about 90%.
Key features of the INSPIRA Cardi-ART include:
- Fast emergency response during CPR
- Rapid cannulation and oxygenated blood delivery
- Monitoring of vital parameters using HYLA blood sensor technology
- Hemodynamic support in case of cardiac failure
Inspira plans to submit the device for FDA regulatory approval as early as 2026, pending the final regulatory pathway.
Inspira Technologies (Nasdaq: IINN) ha lanciato il INSPIRA Cardi-ART, un dispositivo modulare portatile progettato per fornire ossigeno al cervello durante un arresto cardiaco. Questa innovazione si rivolge al mercato globale degli arresti cardiaci di $39,8 miliardi, espandendo il potenziale mercato di Inspira a circa $58,8 miliardi. Il dispositivo ha l'obiettivo di migliorare i tassi di sopravvivenza per i pazienti in arresto cardiaco, in particolare al di fuori degli ospedali, dove il tasso di mortalità è di circa il 90%.
Le caratteristiche principali dell'INSPIRA Cardi-ART includono:
- Risposta rapida in situazioni di emergenza durante la RCP
- Cannulazione rapida e distribuzione di sangue ossigenato
- Monitoraggio dei parametri vitali mediante tecnologia del sensore ematico HYLA
- Sostegno emodinamico in caso di insufficienza cardiaca
Inspira prevede di presentare il dispositivo per l'approvazione normativa della FDA già nel 2026, in attesa del percorso normativo finale.
Inspira Technologies (Nasdaq: IINN) ha presentado el INSPIRA Cardi-ART, un dispositivo modular portátil diseñado para proporcionar oxígeno al cerebro durante un paro cardíaco. Esta innovación se dirige al mercado global de paro cardíaco de $39.8 mil millones, ampliando el mercado potencial de Inspira a aproximadamente $58.8 mil millones. El dispositivo tiene como objetivo mejorar las tasas de supervivencia de los pacientes en paro cardíaco, particularmente fuera de los hospitales, donde la tasa de mortalidad es de aproximadamente el 90%.
Las características clave del INSPIRA Cardi-ART incluyen:
- Respuesta rápida en emergencias durante RCP
- Cannulación rápida y entrega de sangre oxigenada
- Monitoreo de parámetros vitales utilizando tecnología de sensor de sangre HYLA
- Soporte hemodinámico en caso de insuficiencia cardíaca
Inspira planea presentar el dispositivo para la aprobación regulatoria de la FDA lo antes posible, en 2026, a la espera de la vía regulatoria final.
인스피라 테크놀로지스(나스닥: IINN)는 심장 마비 중 뇌에 산소를 공급하기 위해 설계된 휴대용 모듈식 장치인 INSPIRA Cardi-ART를 소개했습니다. 이 혁신은 397억 8천만 달러 규모의 전 세계 심장 마비 시장을 목표로 하여 인스피라의 잠재적인 시장을 약 588억 8천만 달러로 확장합니다. 이 장치는 특히 병원 밖에서 심장 마비 환자의 생존율을 향상시키는 것을 목표로 하며, 이곳의 사망률은 약 90%에 달합니다.
INSPIRA Cardi-ART의 주요 기능에는 다음이 포함됩니다:
- 심폐소생술(CPR) 중 신속한 응급 대응
- 빠른 캐뉼레이션과 산소화된 혈액 전달
- HYLA 혈액 센서 기술을 이용한 생체 신호 모니터링
- 심장 기능 부전 시 혈역학적 지원
인스피라는 2026년 FDA 규제 승인을 위해 장치를 제출할 계획이며, 최종 규제 경로를 기다리고 있습니다.
Inspira Technologies (Nasdaq: IINN) a lancé le INSPIRA Cardi-ART, un dispositif modulaire portable conçu pour fournir de l'oxygène au cerveau pendant un arrêt cardiaque. Cette innovation cible le marché mondial des arrêts cardiaques de 39,8 milliards de dollars, élargissant le marché potentiel d'Inspira à environ 58,8 milliards de dollars. Le dispositif vise à améliorer les taux de survie des patients en arrêt cardiaque, notamment en dehors des hôpitaux où le taux de mortalité est d'environ 90 %.
Les principales caractéristiques de l'INSPIRA Cardi-ART incluent :
- Réaction rapide en cas d'urgence lors de la RCP
- Cannulation rapide et distribution de sang oxygéné
- Surveillance des paramètres vitaux grâce à la technologie des capteurs sanguins HYLA
- Soutien hémodynamique en cas d'insuffisance cardiaque
Inspira prévoit de soumettre le dispositif pour une approbation réglementaire par la FDA dès 2026, en attente du parcours réglementaire final.
Inspira Technologies (Nasdaq: IINN) hat das INSPIRA Cardi-ART eingeführt, ein tragbares modulares Gerät, das dazu dient, das Gehirn während eines Herzstillstands mit Sauerstoff zu versorgen. Diese Innovation zielt auf den globalen Herzstillstandsmarkt von 39,8 Milliarden US-Dollar ab und erweitert das potenzielle Marktvolumen von Inspira auf etwa 58,8 Milliarden US-Dollar. Das Gerät soll die Überlebensraten von Patienten mit Herzstillstand erhöhen, insbesondere außerhalb von Krankenhäusern, wo die Sterblichkeitsrate bei etwa 90 % liegt.
Zu den Hauptmerkmalen des INSPIRA Cardi-ART gehören:
- Schnelle Notfallreaktion während der CPR
- Schnelle Kanülierung und Lieferung von sauerstoffreichem Blut
- Überwachung der Vitalparameter mit HYLA-Blutsensor-Technologie
- Hämodynamische Unterstützung bei Herzversagen
Inspira plant, das Gerät bereits 2026 zur Genehmigung durch die FDA einzureichen, abhängig vom endgültigen regulatorischen Weg.
- Expansion into the $39.8 billion global cardiac arrest market
- Potential to improve survival rates for cardiac arrest patients
- Innovative features including rapid cannulation and vital parameter monitoring
- Planned FDA submission as early as 2026
- Device is still in development phase
- Regulatory approval timeline is uncertain
- Potential competition in the cardiac arrest market
Insights
Inspira Technologies' introduction of the INSPIRA Cardi-ART represents a potentially significant advancement in cardiac arrest treatment. The device's development targets a critical need in emergency medicine, given the high mortality rate of cardiac arrests, especially those occurring outside hospitals.
Key points to consider:
- The device aims to provide oxygen to the brain during cardiac arrest, which is important for improving survival rates and reducing neurological damage.
- With approximately 550,000 annual cardiac arrest events in the U.S., including 350,000 outside hospitals, the potential impact is substantial.
- The current survival rate for out-of-hospital cardiac arrests is less than
10% , highlighting the urgent need for innovative solutions. - The INSPIRA Cardi-ART's portability and modular design could make it suitable for rapid deployment in various settings, both in and outside hospitals.
However, it's important to note that the device is still in development, with regulatory submission to the FDA planned for 2026. This timeline suggests a considerable period before potential market availability, assuming successful trials and approval. The effectiveness and safety of the device will need to be thoroughly demonstrated through clinical trials.
The integration of Inspira's HYLA blood sensor technology for monitoring vital parameters could provide valuable real-time data during resuscitation efforts, potentially improving the quality of care. However, the practical implementation and training required for emergency responders to effectively use this technology in high-stress situations will be important factors to consider.
While the potential market size of
Inspira Technologies' announcement of the INSPIRA Cardi-ART development presents an intriguing opportunity for investors, albeit with several important considerations:
- Market Expansion: The company is targeting a substantial market, with the global cardiac arrest market valued at
$39.8 billion . This expansion from their current focus on the$19 billion mechanical ventilation market could significantly increase their total addressable market to$58.8 billion . - Innovation Premium: If successful, this novel approach to cardiac arrest treatment could command a premium in the market, potentially leading to higher profit margins.
- Regulatory Timeline: The planned FDA submission in 2026 indicates a long runway before potential commercialization. This extended timeline may impact short-term investor sentiment and requires a long-term investment perspective.
- R&D Costs: Development of such a complex medical device will likely require significant R&D investment, which could impact the company's financial position in the near term.
- Market Penetration: While the total market size is large, actual revenue potential will depend on factors such as pricing strategy, adoption rates and competition.
Financially, investors should closely monitor the company's cash burn rate and funding strategy to ensure they can sustain the development process through to commercialization. The company's ability to secure partnerships or additional funding could be important for maintaining momentum.
It's worth noting that as a development-stage company, Inspira Technologies' valuation is likely based more on future potential than current financials. The success of the INSPIRA Cardi-ART could significantly impact the company's valuation, but it also presents considerable risk if development or regulatory hurdles arise.
Investors should also consider the competitive landscape. While this device appears innovative, other companies may be developing similar technologies. Inspira's ability to secure strong intellectual property protection and maintain a technological edge will be critical for long-term success in this market.
Inspira's innovation targets life-saving intervention for patients with cardiac arrest, of which there are approximately 550,000 annual cardiac arrest events in the
The INSPIRA Cardi-ART provides the Company a new market opportunity to target the
RA'ANANA,
The device is expected to expand the next-generation INSPIRA™ ART platform to a wider range of applications with a combined potential market of approximately
The INSPIRA Cardi-ART is being designed to support vital organ oxygenation during cardiac arrest to treat patients both in and outside of hospitals. The Company plans the regulatory submission of the Device to the
Today, nearly
The INSPIRA Cardi-ART portable modular unit is being designed for fast emergency response during CPR (cardio pulmonary resuscitations) in and outside of hospitals, allowing for rapid cannulation and the delivery of oxygenated blood throughout the body to reduce damage to the heart and brain during cardiac arrest. The Device is being designed to monitor key vital parameters using the groundbreaking HYLA blood sensor technology.
The INSPIRA Cardi-ART is being designed to provide quick hemodynamic support in the case of cardiac failure as it drains blood, exchanges gases, and then returns the blood to the arterial system to maintain systemic perfusion. The technique has been used in other procedures that have been recommended in medical guidelines as set out by the American Heart Association (AHA).
Dr. Dekel Stavi, Inspira Technologies' Medical Director, stated: "The INSPIRA Cardi-ART may become the difference between life and death during a cardiac arrest event, where the medical team sometimes has only minutes to provide critical life-saving care."
About Cardiac Arrest
In
Cardiac arrest results in the onset of coma within 10–20 seconds due to the lack of oxygen delivery to the brain and loss of neuronal function. Unless the circulation is quickly restored, the lack of oxygen delivery to the brain leads to the death of neurons over 5–40 minutes.
As part of a global endeavor to enhance patient outcomes, medical centers worldwide have began to adopt extracorporeal techniques to restore oxygenation and circulation for patients having both IHCA and OHCA. In such critical scenarios, if administered early enough, it provides healthcare professionals with valuable time to stabilize the patient and identify the underlying cause of cardiac arrest.
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies targets to reshape the respiratory and life-support landscape. We are developing novel expanding life support technologies with Inspira blood oxygenation and blood monitoring technologies. Inspira is on a quest to become the leading ground-breaking medical device company in our field with business alliances around the world.
The INSPIRA™ ART (Gen 2), also known as the INSPIRA™ ART500, will include the Company's Adaptive Blood Oxygenation technology and is being designed to continuously measure the patient's blood parameters in real-time, delivering needed oxygen volume straight into the blood. By elevating patient oxygen saturation levels in minutes, this technology potentially allows patients to remain awake during treatment and therefore may enable patients to be treated in and beyond intensive care units, reducing the need for mechanical ventilation systems that require intubation and medically induced coma.
The Company's INSPIRA™ ART100 system received FDA 510(k) clearance for Cardiopulmonary Bypass procedures and AMAR certification for Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.
The Company's other products, including the INSPIRA™ ART (Gen 2) including the INSPIRA Cardi-ART portable modular device and HYLA™ blood sensor are currently being designed and developed, and have not yet been tested or used in humans and have not been approved by any regulatory entity.
For more information, please visit our corporate website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to
* https://www.maximizemarketresearch.com/market-report/global-cardiac-arrest-treatment-market/36103/
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved.
Logo - https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/inspira-technologies-introduces-the-inspira-cardi-art-aiming-to-provide-oxygen-to-the-brain-during-cardiac-arrest-302209756.html
SOURCE Inspira Technologies
FAQ
What is the INSPIRA Cardi-ART device developed by Inspira Technologies (IINN)?
What is the target market size for Inspira Technologies' (IINN) INSPIRA Cardi-ART?
When does Inspira Technologies (IINN) plan to submit the INSPIRA Cardi-ART for FDA approval?
What are the key features of Inspira Technologies' (IINN) INSPIRA Cardi-ART device?
